Inactief instrument

Andere talen Anthera Pharmaceuticals Inc Nasdaq

Aandelen

US03674U3005

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Anthera Pharmaceuticals, Inc.(OTCPK:ANTH) dropped from S&P TMI Index	02-07-18
Anthera Pharmaceuticals, Inc.(OTCPK:ANTH) dropped from NASDAQ Composite Index	27-06-18
Anthera Pharmaceuticals, Inc. Reports Top Line Data from the Result Phase 3 Clinical Study of Sollpura	12-03-18
Anthera Mulls Acquisitions	06-03-18
Anthera Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2017	05-03-18
Anthera Pharmaceuticals, Inc. Concludes Last Patient Visit in the Phase 3 Result Clinical Study of Sollpura	05-02-18
Anthera Pharmaceuticals, Inc. announced that it has received $15 million in funding from a group of investors	09-01-18
Anthera Pharmaceuticals, Inc. Appoints Patrick Murphy as Senior Vice President, Manufacturing	03-01-18
Anthera Pharmaceuticals, Inc. Announces Positive Outcome of Interim Futility Analysis in the Phase 3 Result Clinical Study of Sollpura	11-12-17
Anthera Pharmaceuticals Announces Completion of Recruitment in the Phase 3 RESULT Clinical Study of Sollpura	09-11-17
Anthera Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017	06-11-17
Anthera Pharmaceuticals, Inc. announced that it expects to receive $15 million in funding from a group of investors	23-10-17
Anthera Pharmaceuticals, Inc. Announces Top Line Final Data from Phase 2 BRIGHT-SC Study of Blisibimod	28-08-17
Anthera Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2017	09-08-17
Anthera Pharmaceuticals, Inc. Announces Executive Changes	14-07-17
Anthera Pharmaceuticals, Inc. Announces Commencement of Screening in European Sites in Phase 3 Result Clinical Study of Sollpura	06-07-17
Anthera Pharmaceuticals, Inc.(NasdaqGM:ANTH) dropped from Russell 3000 Index	23-06-17
Anthera Pharmaceuticals, Inc.(NasdaqGM:ANTH) dropped from Russell 2000 Index	23-06-17
Anthera Pharmaceuticals, Inc.(OTCPK:ANTH) dropped from Russell 2000 Dynamic Index	23-06-17
Anthera Pharmaceuticals Announces Resignation of Klara Dickinson-Eason as Senior Vice President, Chief Regulatory Officer, Effective June 20, 2017	19-06-17

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Anthera Pharmaceuticals Inc Nasdaq

Aandelen

US03674U3005

Andere talen

Filters